Ligia Berci, MD
Child & Adolescent Psychiatry · Sacramento, CANPI 1932213543
Payments from drug & device makers
Across 43 payments — averaging $22.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$300
- Johnson & Johnson$229
- Otsuka America Pharmaceutical, Inc.$108
- Alkermes, Inc.$86
- Indivior Inc.$81
- E.r. Squibb & Sons, L.L.C.$76
- plus $84 from 4 others
What the payments were for
- Food & beverage$964100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 14 | $300 |
| Johnson & Johnson | 8 | $229 |
| Otsuka America Pharmaceutical, Inc. | 5 | $108 |
| Alkermes, Inc. | 4 | $86 |
| Indivior Inc. | 4 | $81 |
| E.r. Squibb & Sons, L.L.C. | 3 | $76 |
| Sunovion Pharmaceuticals Inc. | 2 | $31 |
| AbbVie | 1 | $25 |
| Neurocrine Biosciences, Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $11 |
How this compares
$964 in reported general payments places this provider in the 75th percentile of 434 child & adolescent psychiatry providers in California.
See all child & adolescent psychiatry providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Divalproex Sodium ErDivalproex Sodium | 20 | $478 |
| Oxcarbazepine | 19 | $474 |
| Olanzapine | 29 | $431 |
| Quetiapine Fumarate | 14 | $186 |
| Hydroxyzine Pamoate | 27 | $165 |
| Benztropine Mesylate | 21 | $158 |
| Trazodone Hcl | 11 | $77 |
Paid to pharmacies, not to this prescriber.
Other child & adolescent psychiatry in Sacramento
- Manpreet SinghSacramento$238K
- Kevin CoxOjai$2.9M
- Sarah LeeRiverside$735K
- Eliot MoonPasadena$522K
- Robert HendrenSan Francisco$486K
- Michael McManusSan Diego$426K
- Sukhjit BrarFresno$283K
- Antonio HardanPalo Alto$160K
- Shirley LiuSan Jose$143K
- Ihab SolimanCorona del Mar$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.